The Cytokine Storm Company

Recent Publications

The Lancet Respiratory Medicine – Peer-Review:

Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial

Journal of Medical Economics: Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective

medRxiv: Early lenzilumab treatment of COVID-19 patients using c-reactive protein as a biomarker improves efficacy: results from the phase 3 ‘LIVE-AIR’ trial

We are a clinical stage biopharmaceutical company, developing our immunology and immuno-oncology portfolio of monoclonal antibodies. We are focusing our efforts on the development of our lead product candidate, lenzilumab, our proprietary Humaneered® (“Humaneered”) anti-human granulocyte-macrophage colony-stimulating factor (“GM-CSF”) monoclonal antibody.